173 related articles for article (PubMed ID: 6761866)
21. Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial.
Judson I; Verweij J; Gelderblom H; Hartmann JT; Schöffski P; Blay JY; Kerst JM; Sufliarsky J; Whelan J; Hohenberger P; Krarup-Hansen A; Alcindor T; Marreaud S; Litière S; Hermans C; Fisher C; Hogendoorn PC; dei Tos AP; van der Graaf WT;
Lancet Oncol; 2014 Apr; 15(4):415-23. PubMed ID: 24618336
[TBL] [Abstract][Full Text] [Related]
22. Results of the Royal Marsden Hospital second soft tissue sarcoma schedule (STS II) chemotherapy regimen in the management of advanced sarcoma.
Bryant BM; Wiltshaw E
Cancer Treat Rep; 1980; 64(4-5):689-92. PubMed ID: 7000348
[TBL] [Abstract][Full Text] [Related]
23. [Ifosfamide in the treatment of small cell carcinoma of the lung].
Mukouda K; Morikawa E; Hasegawa K; Noumi K; Ohmura T; Mishima Y; Kawamoto M; Inagaki A; Kamitsuna A; Yamakido M; Nishimoto Y; Koyama T; Katsuta S
Gan To Kagaku Ryoho; 1983 May; 10(5):1293-8. PubMed ID: 6307164
[TBL] [Abstract][Full Text] [Related]
24. Results of single-agent and combination chemotherapy for advanced soft tissue sarcomas. Implications for decision making in the clinic.
Demetri GD; Elias AD
Hematol Oncol Clin North Am; 1995 Aug; 9(4):765-85. PubMed ID: 7490240
[TBL] [Abstract][Full Text] [Related]
25. Chemotherapy of advanced sarcomas of bone and soft tissue.
Antman KH
Semin Oncol; 1992 Dec; 19(6 Suppl 12):13-20. PubMed ID: 1485169
[TBL] [Abstract][Full Text] [Related]
26. High-dose ifosfamide in bone and soft tissue sarcomas: results of phase II and pilot studies--dose-response and schedule dependence.
Patel SR; Vadhan-Raj S; Papadopolous N; Plager C; Burgess MA; Hays C; Benjamin RS
J Clin Oncol; 1997 Jun; 15(6):2378-84. PubMed ID: 9196153
[TBL] [Abstract][Full Text] [Related]
27. Drug management of malignant disease.
Fennelly JJ
Ir Med J; 1983 Jul; 76(7):326-31. PubMed ID: 6350216
[No Abstract] [Full Text] [Related]
28. High-dose ifosfamide for soft tissue sarcomas: set the scene, or senescence?
Verweij J
Ann Oncol; 1998 Aug; 9(8):807-9. PubMed ID: 9789601
[No Abstract] [Full Text] [Related]
29. Chemotherapy of sarcomas-a perspective.
Sutow WW; Maurer HM
Semin Oncol; 1981 Jun; 8(2):207-14. PubMed ID: 6166986
[No Abstract] [Full Text] [Related]
30. Ifosfamide in paediatric oncology: tried but not tested?
Shaw PJ; Eden T
Lancet; 1990 Apr; 335(8696):1022-3. PubMed ID: 1970073
[No Abstract] [Full Text] [Related]
31. [Ifosfamide in pediatric malignancy--experiences in the Northern Israel Oncology Center].
Roguin A; Ben Arush MW; Higasi A; Kuten A
Harefuah; 1996 Apr; 130(8):511-4, 584. PubMed ID: 8765870
[TBL] [Abstract][Full Text] [Related]
32. The role of ifosfamide in the treatment of adult soft tissue sarcomas, Ewing's sarcoma, and osteosarcoma: a review.
Dirix LY; Van Oosterom AT
Semin Oncol; 1990 Apr; 17(2 Suppl 4):50-7. PubMed ID: 2185547
[TBL] [Abstract][Full Text] [Related]
33. N-acetylcysteine and ifosfamide in the treatment of unresectable pancreatic adenocarcinoma and refractory testicular cancer.
Loehrer PJ; Williams SD; Einhorn LH
Semin Oncol; 1983 Mar; 10(1 Suppl 1):72-5. PubMed ID: 6836331
[No Abstract] [Full Text] [Related]
34. Megatherapy for soft tissue sarcomas. EBMT experience.
Pinkerton CR
Bone Marrow Transplant; 1991; 7 Suppl 3():120-2. PubMed ID: 1713088
[No Abstract] [Full Text] [Related]
35. The efficacy of a combination of etoposide, ifosfamide, and cisplatin in the treatment of patients with soft tissue sarcoma.
Pápai Z; Bodoky G; Szántó J; Poller I; Rahóty P; Eckhardt S; Láng I; Szendroi M
Cancer; 2000 Jul; 89(1):177-80. PubMed ID: 10897015
[TBL] [Abstract][Full Text] [Related]
36. Response to mesna, doxorubicin, ifosfamide, and dacarbazine in 108 patients with metastatic or unresectable sarcoma and no prior chemotherapy.
Elias A; Ryan L; Sulkes A; Collins J; Aisner J; Antman KH
J Clin Oncol; 1989 Sep; 7(9):1208-16. PubMed ID: 2504890
[TBL] [Abstract][Full Text] [Related]
37. [Clinical experiences with holoxan within the framework of sequential combination therapy (author's transl)].
Hartwich G; Neidhardt B; Lutz H
Med Klin; 1978 Sep; 73(36):1247-52. PubMed ID: 692477
[TBL] [Abstract][Full Text] [Related]
38. Cisplatin (cis-diamminedichloroplatinum II).
Prestayko AW; D'Aoust JC; Issell BF; Crooke ST
Cancer Treat Rev; 1979 Mar; 6(1):17-39. PubMed ID: 378370
[No Abstract] [Full Text] [Related]
39. Response to ifosfamide and mesna: 124 previously treated patients with metastatic or unresectable sarcoma.
Antman KH; Ryan L; Elias A; Sherman D; Grier HE
J Clin Oncol; 1989 Jan; 7(1):126-31. PubMed ID: 2491883
[TBL] [Abstract][Full Text] [Related]
40. [The effects of high-dose ifosfamide in the treatment of bone and soft tissue sarcomas].
Ishii T; Tatezaki S; Satoh T; Yonemoto T; Umeda T; Kitoh M
Gan To Kagaku Ryoho; 1997 Nov; 24(14):2123-30. PubMed ID: 9388523
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
